Welcome to our dedicated page for Wuxi Biologics news (Ticker: WXXWY), a resource for investors and traders seeking the latest updates and insights on Wuxi Biologics stock.
WuXi Biologics provides contract research, development and manufacturing organization services for biologics, supporting clients from discovery through development and commercial manufacturing. News for WXXWY commonly covers the company's CRDMO operations, biologics manufacturing capacity, quality systems, and technologies used in antibody and complex protein production.
Recurring updates include launches and enhancements to platforms such as WuXia™, TrueSite TI™, WuXia293Stable and WuXiUP™, as well as GMP certifications, regulatory inspections, sustainability ratings, industry awards, interim results, integrated project activity and global operating capacity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
WuXi Biologics has been awarded the 2023 ISPE Facility of the Year Award (FOYA) in the Operations category for its manufacturing facility in Dundalk, Ireland. The facility, one of the largest of its kind in Europe, features two manufacturing areas with 6x1KL single-use bioreactors for perfusion and 12x4KL single-use bioreactors for fed-batch. Construction of the 467,500-square-foot greenfield facility began in December 2018 and operations started in December 2021, creating over 6,000 construction jobs and more than 500 highly skilled jobs in the region.
The facility received its first GMP certificate from the Irish Health Products Regulatory Authority (HPRA) just nine months after starting operations. In line with WuXi Biologics' ESG strategy, the site incorporates sustainable concepts, including 100% renewable energy power supply. This marks the second FOYA recognition for WuXi Biologics, following an Honorable Mention in 2014 for its facility in Wuxi city, China.
Summary not available.
Summary not available.